Executive Summary
CDMOs are operating in a market that is growing rapidly in both scale and complexity. As pipelines diversify and modalities fragment, execution risk has become as important to sponsors as scientific capability or capacity. In this environment, operational maturity is no longer optional. It is a primary driver of competitiveness, sponsor trust, and long-term growth.
ERP maturity sits at the center of this shift. For modern CDMOs, ERP is not a back-office system but the operational backbone that connects manufacturing execution, quality oversight, inventory control, project economics, and financial performance. When these functions operate in silos, organizations experience slower releases, higher compliance risk, margin leakage, and limited visibility into program performance.
In a market where growth exposes weaknesses quickly, ERP maturity becomes a strategic asset. CDMOs that get it right position themselves to scale with confidence, protect margins, and strengthen sponsor relationships. Those that do not often find their growth constrained not by demand, but by their ability to execute.
CDMOs that invest in well-architected ERP foundations benefit from faster and more predictable execution. Integrated systems shorten deviation investigations, improve batch release timelines, support accurate project accounting, and provide inspection-ready traceability by design. These capabilities directly reduce operational risk while enabling scale across modalities, sites, and acquisitions.
Equally important is how ERP is implemented. Successful CDMO ERP programs are phased, modality-aware, and grounded in GxP requirements from the start. Platforms with pre-built support for regulated manufacturing, combined with experienced implementation partners who understand CDMO operating realities, consistently deliver shorter timelines, lower total cost, and fewer post–go-live corrections.
The Evolution of the CDMO
From Outsourcing Vendors to Strategic Partners
Contract development and manufacturing organizations, or CDMOs, have evolved from tactical outsourcing vendors into strategic capacity and capability partners. This shift is driven by pipelines that are richer but more complex, modalities that no longer fit traditional manufacturing plants, tighter regulatory expectations, and sponsors seeking speed without taking on fixed manufacturing overhead.
A Market Expanding in Size, Complexity, and Expectation
The CDMO market has grown rapidly alongside this shift. Global CDMO spending is estimated at approximately $240–260 billion in the mid‑2020s and is projected to reach roughly $500–600 billion by the mid‑2030s, reflecting sustained high single‑digit to low double‑digit annual growth. This expansion is supported by continued private investment and consolidation, as CDMOs add capabilities and scale to meet increasing sponsor demand.
How CDMOs Are Evaluated Has Fundamentally Changed
As a result, CDMOs are no longer evaluated solely on whether they can manufacture a product. They are assessed on their ability to reduce end-to-end risk, accelerate timelines, and operate as an extension of the sponsor organization.
Why Execution Infrastructure Now Matters
This whitepaper focuses on what it takes to execute in this environment, with an emphasis on how successful ERP implementation has become a critical enabler of scale, compliance, and operational discipline. As CDMOs scale across modalities, geographies, and regulatory regimes, ERP platforms increasingly define how effectively organizations execute, demonstrate control, and grow.
What is Changing in the CDMO Market
Capacity is no longer the only story
For years, capacity was the defining constraint in the CDMO market. While capacity still matters, sponsors now prioritize risk reduction and execution reliability over raw volume. They expect CDMOs to deliver strong development services, disciplined technology transfer, analytical depth, digital quality systems, and program management that mirrors internal operations.
CDMOs that succeed today are those that demonstrate repeatable execution across development, scale-up, and commercial supply.
Modality specialization is accelerating
The market is increasingly organized around specialized modalities. A CDMO that excels in high-potency small molecules is not automatically well suited for peptides or radiopharmaceuticals. Sponsors now assemble portfolios of CDMO partners aligned to specific modalities rather than relying on a single, generalized provider.
This specialization raises the bar for operational systems, as each modality introduces distinct timelines, inventory behaviors, and compliance requirements.
Compliance and data integrity as differentiators
Leading organizations treat data integrity as a core operational capability rather than an administrative function.
As regulatory scrutiny increases, sponsors place greater emphasis on traceability and inspection readiness. CDMOs are evaluated on their control over deviations, change management, training, and validation. Leading organizations treat data integrity as a core operational capability rather than an administrative function.
From a systems perspective, this requires a validated quality management system with 21 CFR Part 11–compliant electronic records and electronic signatures, tightly integrated with manufacturing, inventory, and training data so that quality status is visible at the point of execution.
CDMO Modality Overview and ERP Design Considerations
Pricing pressure meets operational complexity
Sponsors continue to push for predictable pricing and shorter timelines, even as manufacturing becomes more complex. Bespoke equipment, specialized raw materials, cold chain requirements, and shielded infrastructure all add cost and execution risk. In response, CDMOs are adopting platform approaches, standardized technology transfer models, and more rigorous planning disciplines.
Across all modalities, modern ERP environments for CDMOs typically include tightly integrated modules for financial management, manufacturing execution, inventory and lot traceability, project management and project accounting, order management, procurement, employee health and safety (EHS) tracking where required, and a regulated quality management system with 21 CFR Part 11 compliance. The emphasis and configuration of these modules varies significantly by modality.
While overall market growth is strong, it is uneven across modalities. Each CDMO type operates under distinct constraints related to time sensitivity, inventory behavior, quality timelines, regulatory complexity, and operational execution.
Small Molecule CDMOs
Overview: Small molecule CDMOs remain the backbone of outsourced manufacturing. The competitive focus has shifted from basic manufacturability to reliable, compliant, and timely execution across development and commercial supply.
Key Trends
- Rising demand for high potency and containment capabilities driven by oncology pipelines
- Adoption of continuous manufacturing and process intensification to reduce cycle time and improve robustness
- Expansion of integrated offerings from route scouting through commercial supply
- Increased emphasis on analytical services and impurity profiling
Common Pitfalls
- Gaps between sponsor development data and manufacturing execution during tech transfer
- Weak planning for long lead-time reagents, specialty excipients, and APIs
- Fragmented quality, manufacturing, and financial systems that slow batch release
Operational Characteristics
- Time sensitivity: Moderate. Delays primarily impact cost rather than product viability
- Inventory behavior: Stable with long shelf life, but yield sensitive
- Release: Days to weeks, driven by analytical testing
- Regulatory: GxP-focused with added hazard requirements
Recommended ERP Features
- Financials with advanced cost accounting
- Project accounting for tech transfer
- Batch & work order execution
- Inventory with expiration control
- Materials planning & procurement
- QMS with 21 CFR Part 11 records
Peptide CDMOs
Overview: Peptide CDMOs operate at the intersection of chemical synthesis and biologics-like rigor. Growth is driven by metabolic disease, oncology, and specialty indications.
Key Trends
- Investment in large-scale solid phase synthesis and purification capacity
- Differentiation through high-resolution analytical capability
- Growth of peptide conjugates and specialized chemical modifications
- Increased focus on raw material control and faster development cycle times
Common Pitfalls
- Underestimating purification complexity and yield loss for long sequences
- Limited visibility into resin usage, solvent consumption, and true cost drivers
- Quality documentation that lacks strong linkage to development rationale
Operational Characteristics
- Time sensitivity: Moderate timeline pressure
- Inventory: Yield-sensitive during synthesis
- Release: Driven by complex analytical testing
- Regulatory: Focus on analytical justification
Recommended ERP Features
- Project accounting for development
- Batch manufacturing with lot tracking
- Resin & solvent inventory management
- Milestone-based revenue management
- QMS with OOS & deviation tracking
Nuclear Medicine and Radiopharmaceutical CDMOs
Overview: Nuclear medicine CDMOs operate under extreme time and regulatory constraints. Short isotope half-lives fundamentally reshape manufacturing, quality, and financial processes.
Key Trends
- Expansion of regional manufacturing networks for just-in-time production
- Increased focus on chain of custody and environmental monitoring
- Deeper integration with logistics partners and clinical sites
- Growing need for transparent scheduling and slot management
Common Pitfalls
- Manual scheduling and paper-driven execution
- Limited visibility into yield, scrap, and deviations
- Complex revenue recognition tied to dose counts and delivery windows
- Training and qualification gaps that surface during inspections
Operational Characteristics
- Time sensitivity: Extreme decay pressure
- Inventory behavior: Dynamic, driven by radioactive decay calculations
- Release: Measured in hours, often overlapping with shipment
- Regulatory: GxP plus NRC, DOT, and state radiation control
Recommended ERP Features
- Time-stamped manufacturing and work order execution
- EHS tracking for radiation exposure and incident management
- Inventory management with decay-aware quantities
- Order management and billing based on dose or activity
- Asset tracking for hot cells and shielding systems
Biologics, Cell, and Gene Therapy CDMOs
Overview: Biologics, cell, and gene therapy CDMOs support complex regulated environments involving living systems or patient-specific materials.
Key Trends
- Growth in monoclonal antibodies, viral vectors, and cell-based therapies
- Demand for flexible, small-batch and patient-specific manufacturing models
- Emphasis on chain of identity and chain of custody across the supply chain
- Heightened regulatory scrutiny as therapies move to commercial stages
Common Pitfalls
- Insufficient traceability across materials, batches, and patients
- Manual or disconnected tracking of chain of identity and custody
- Limited visibility into labor and true program costs
- Difficulty scaling processes from clinical to commercial manufacturing
Operational Characteristics
- Time sensitivity: High, particularly for autologous therapies
- Inventory behavior: Highly constrained, cold-chain dependent
- Release: Driven by complex testing and regulatory documentation
- Regulatory: GxP plus biologics and viral safety requirements
Recommended ERP Features
- Strong chain of identity and chain of custody controls
- Inventory support for cold chain and limited shelf life
- Detailed labor tracking and resource management
- Project-based costing for clinical and commercial runs
WMS in Sterile Injectable and Radiopharma CDMO Operations
In sterile injectable and radiopharmaceutical CDMOs, warehouse operations directly determine manufacturing viability, product integrity, and regulatory compliance. Materials must be controlled at a granular level as they move through quarantine, sampling, cleanroom staging, production, inspection, and shipment under strict time and environmental constraints. In this context, a WMS functions as a regulated execution system, not a warehouse utility.
For sterile operations, WMS enforces container-level control over primary packaging components, consumables, and intermediates, ensuring that only released materials are staged and issued to production. In radiopharmaceutical operations, where product value decays continuously after production, WMS must also support time-based inventory behavior, controlled zones, and chain-of-custody requirements. When tightly integrated with ERP, quality, and manufacturing execution, WMS reduces execution risk, supports accurate costing, and strengthens inspection readiness.
CDMO-specific WMS features for sterile injectables and radiopharma
A WMS supporting these modalities should provide:
- Container-level traceability for vials, syringes, cartridges, stoppers, and packaging components
- Parent–child genealogy linking containers to lots, batches, kits, and shipments
- Selective quarantine and release at the container level without impacting full lots
- FEFO and expiry-based picking enforced at the container level
- Scan-driven workflows for receiving, cleanroom staging, line loading, filling, inspection, packaging, and shipment
- Location and environmental zone tracking, including cleanrooms, cages, and controlled radiation areas
- Time-based inventory logic to support radioactive decay and short half-life materials
- Chain of custody and audit trails capturing every movement and handoff
- Serialization and aggregation across container, case, pallet, and shipper
- Integration with ERP, quality systems, EHS, and project accounting
Where Systems Break Down and Where the Competitive Advantage Lies for CDMOs
For sterile injectable and radiopharmaceutical CDMOs, WMS maturity is inseparable from execution maturity. Without container-level control, scan-driven workflows, and integrated quality enforcement, warehouse operations quickly become a bottleneck to scale and compliance rather than a foundation for reliable growth.
As CDMOs invest in facilities and talent, growth is often constrained by operational infrastructure. Disconnected systems, limited end-to-end traceability, margin leakage from complex contracts, and lack of standardization across sites can slow execution and increase risk.
In an increasingly specialized and consolidated market, execution discipline has become a defining differentiator. CDMOs that demonstrate connected processes, reliable metrics, and inspection-ready operations reduce sponsor risk and strengthen long-term partnerships.
ERP implementations succeed when they are treated as operational transformation programs rather than IT projects.
As CDMOs grow in scale and complexity, the success of an ERP initiative depends less on software selection and more on how well the implementation aligns with regulated operations, modality-specific workflows, and long-term growth plans. In the CDMO industry, ERP implementations succeed when they are treated as operational transformation programs rather than IT projects.
What Successful ERP Implementation Looks Like in the CDMO Industry
A successful ERP implementation in a CDMO environment delivers three outcomes simultaneously: operational control, regulatory confidence, and business scalability. Practically, this means:
- A single, trusted system of record connecting execution, quality events, inventory, and finance.
- Modality-aware process design reflecting actual chemical and biologics operations.
- Embedded quality and compliance where 21 CFR Part 11 records are part of everyday execution.
- Real-time visibility without manual reconciliation.
Common ERP Pitfalls in CDMOs
Despite significant investment, many ERP initiatives underperform in CDMO environments. The most common pitfalls include:
- Treating ERP as a finance-first system and retrofitting regulated manufacturing operations late in the process
- Applying generic manufacturing templates that ignore modality-specific constraints, yields, and timelines
- Separating ERP, WMS, and QMS design, leading to broken traceability and slow investigations
- Underestimating the effort required for GxP data migration, cleansing, and computer system validation
- Attempting to solve every operational requirement in a single go-live rather than taking a phased approach
Phasing ERP Implementations for CDMO Success
Successful CDMOs approach ERP implementation in deliberate phases, balancing speed with regulatory and operational risk.
Phase 1: Core operational foundation – Focuses on financials, order management, procurement, core inventory, and basic manufacturing execution. Establishing clean master data, lot traceability, and core reporting creates the immediate control and visibility needed to scale.
Phase 2: Quality and program integration – Embeds quality processes, including deviations, CAPA, change control, and 21 CFR Part 11–compliant approvals, directly into manufacturing workflows while expanding project tracking and costing depth.
Phase 3: Modality-specific optimization – Introduces advanced workflows for peptides, nuclear medicine, and advanced therapies, where yield sensitivity, radioactive decay, or patient-specific controls drive significant operational complexity.
Phase 4: Scale and readiness – Standardizes data and processes to support new sites, new modalities, and post-acquisition integration without disrupting GxP operations or compliance readiness.
Why Pre-Built CDMO Processes Matter in ERP Implementations
ERP implementations in CDMOs succeed when they start from a foundation that already reflects regulated manufacturing reality. Platforms with pre-built support for batch execution, lot traceability, project-based work, and quality-controlled workflows allow Phase 1 to focus on execution rather than design.
In practice, leading ERP platforms such as NetSuite have emerged as strong fits for CDMO environments because they provide a unified architecture adapted to multi-modality operations without excessive customization. Combined with a partner invested in CDMO-specific models, organizations apply proven structures from day one.
Phased programs are most effective when led by partners who understand CDMO operating nuances. Early architectural decisions prevent downstream rework, lower total implementation cost, and ensure system support from the first go-live.
Why CDMO ERP projects fail when built from scratch
- Core manufacturing and quality processes are over-customized
- Generic templates ignore modality-specific constraints and timelines
- ERP and QMS are designed separately, breaking traceability
- Too much scope is forced into Phase 1, increasing disruption
- Best practices are learned after go-live rather than applied upfront
Conclusion
As the CDMO market continues to grow and fragment by modality, execution discipline has become the true differentiator. ERP, when designed and implemented with an understanding of regulated CDMO operations, enables faster execution, stronger compliance, and scalable growth. The organizations that treat ERP as strategic infrastructure rather than a back-office tool are best positioned to meet sponsor expectations and manage complexity over time. In an increasingly competitive market, getting ERP right is no longer optional.
Glossary
GxP (Good x Practice) — A collective term for quality guidelines and regulations, including GMP, GCP, and GLP, that ensure products are safe, effective, and traceable throughout their lifecycle.
OOS (Out of Specification) — A test result that falls outside approved acceptance criteria, triggering a formal investigation and documented quality response.
CAPA (Corrective and Preventive Action) — A structured process used to investigate the root cause of deviations or quality events and implement actions to prevent recurrence.
CoI / CoC (Chain of Identity / Chain of Custody) — Controls used to ensure that materials, batches, or patient-specific products are correctly identified and tracked throughout manufacturing, handling, and distribution, particularly critical in biologics and cell and gene therapy.